a Background: In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns.
Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns.
Methods: Stored plasma from 349 adult patients on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens was assayed for HIV-1 RNA viral load, and samples with more than 1000 copies/ml were sequenced in the pol gene. Analysis for resistance mutations utilized the IAS-US 2011 Drug Resistance Mutation list.
Introduction
Unprecedented scale-up of antiretroviral therapy (ART) for over 2.4 million HIV-positive patients in resourcelimited countries has been achieved through the support of the President's Emergency Plan For AIDS Relief (PEPFAR) in partnership with the Global Fund to fight AIDS, Tuberculosis and Malaria and national governments [1] . There is mounting evidence that monitoring clinical and immunological parameters, as opposed to HIV-1 RNA viral loads, may increase HIV-1 drug-resistant mutations and therefore limit options for second-line regimens [2] [3] [4] . New WHO guidelines recommend either tenofovir (TDF) or zidovudine (ZDV) as the preferred nucleoside reverse transcriptase inhibitor (NRTI) for first-line regimens [5] , but there is an increased focus on using TDF because its drug resistance patterns lead to less resistance in alternative thymidine analog drugs [6] . However, there are limited reported data comparing drug resistance patterns between TDF or ZDV containing first-line regimens and their impact on second-line options in low-resource settings.
Nigeria's HIV-1 prevalence rate of 4.4% combined with a population of over 140 million generates the second highest HIV/AIDS burden in the world [7] , dominated by subtypes G and CRF02_AG [8] [9] [10] . In 2002, the government of Nigeria began providing subsidized ART [11] , which expanded in 2005 through PEPFAR-supported HIV/AIDS treatment services, to treat over 300 000 Nigerians by the end of 2009 [12] .
There is evidence that with ART exposure, non-B subtypes may have genetic differences contributing to their pattern of drug resistance [13] [14] [15] [16] ; and thus, mutations arising in Nigeria's diverse subtype population could have cross-resistance to second-line options. In this study, we report antiretroviral drug-resistant mutations from Nigerian patients failing different first-line regimens and predict second-line NRTI options for effective longterm HIV treatment.
Methods
We conducted a retrospective cross-sectional study performing genotypic sequencing analysis on pre-existing blood samples from patients who received targeted viral load testing to confirm virological failure.
Study population
The Institute for Human Virology-Nigeria (IHVN), a PEPFAR implementing partner, provides ART to over 60 000 public sector patients through the AIDS Care and Genotypic analysis of the HIV pol region was performed through nested PCR of protease (codons 1-99) and the amino terminus (codons 1-242) using methods described previously [18] . Amplification products were sequenced with Applied Biosystems 3130 automated sequencer (Applied Biosystems, Foster City, California, USA), assembled using Sequencher 4.2.2 (Gene Codes Corporation, Ann Arbor, Michigan, USA), and aligned with standard subtype references (MacGDE). Phylogenetic analysis was conducted using neighbor-joining and maximum parsimony bootstrap computation [19, 20] .
Viral sequences outside subtype clusters were analyzed using Simplot, v3.4 for inter-subtype recombination [21] .
Drug resistance mutation analysis
Frequencies of drug-resistant mutations were estimated using ViroScore v8.1 [22] and categorized as NRTI and NNRTI-associated mutations according to the International AIDS Society-USA 2011 list [23] . Thymidine analog mutations (TAMs) included M41L, D67N, K70R, L210W, T215F/Y, and K219E/Q that were further designated as TAM 1 (M41-L210-T215Y) or TAM 2 (D67-K70-T215F-K219) [24] . Etravirine resistance was calculated using weighted scores [23] , in which L100I, K101P, and Y181C/I/V result in the greatest impaired clinical response. The number of patients with zero, single, or multiple mutations was categorized within each first-line regimen. Phenotypic resistance patterns, susceptible (S), intermediate (I), or resistant (R), were predicted from a sum of scored mutations according to the Stanford Database Algorithm v1.2 [25] . Protease sequences were analyzed for amino acid substitutions at positions previously reported to be associated with protease inhibitor resistance in subtype B virus [26] .
Statistical analysis
Descriptive analyses were conducted using x 2 and Fisher's exact test, and Student's t-test and Mann-Whitney test, when appropriate. Univariate and multivariate logistic regressions were performed to identify factors associated with mutation patterns. Factors associated at the P less than 0.2 level with the outcome and potential confounders were included in multivariate models. Akaike's Information Criterion (AIC) was used for model selection and the Hosmer-Lemeshow test for goodness of fit. Statistical analyses were performed using SAS (9.1.3; SAS Institute Inc., Cary, North Carolina, USA).
Results
The study population consisted of a cross-sectional sample of 349 patients who received targeted viral load testing. Of the 205 samples designated for genotyping, 30 failed to amplify (n ¼ 175). At viral load testing, 52% of the patients were female, mean age was 38 years, median time on ARTwas 27 months, and median CD4 cell count was 128 cells/ml [interquartile range (IQR) 60-229].
Of those patients genotyped, 14% were on ZDV, 21% on d4T, 13% on TDF, and 52% on more than one NRTI. For those with multiple NRTIs, 26% were prescribed ZDV and d4T sequentially and in either order. The remaining 25% were prescribed ZDV or d4T initially, before substituting either of them with TDF. There was variation in HIV-1 subtypes with most patients harboring subtype G virus and CRF02_AG. Fewer than 6% had subtypes A, B, and C virus. Those who were genotyped were significantly more likely to have prior ART, more than 24 months of ART exposure, and lower CD4 cell counts at viral load testing (Table 1) . There were no significant differences between patients whose samples did and did not amplify (data not shown).
Nucleoside reverse transcriptase inhibitor resistance Among all patients genotyped, 94% had at least one NRTI mutation and 62% had at least one TAM mutation. The average number of NRTI mutations was three with a range of 0-8. Most (90%) patients harbored the M184V/I mutation and 14% had the K65R mutation. M184V was the only mutation that was associated with a lower average HIV-1 RNA viral load (4.7 vs. 5.1 log 10 copies/ml; P ¼ 0.01).
Patients on TDF-based regimens were significantly more likely to have thymidine-sparing mutations [K65R (57%), M184I (30%), Y115F (13%)] as compared to ZDV and d4T-based regimens (P 0.02). Conversely, patients on TDF-based regimens were less likely to have TAM mutations ( Table 2 ). The two patients on TDF-based regimens with a TAM mutation (K219E) also had the K65R mutation. In multivariate analysis, TDF-based regimens were less likely to have three or more NRTIassociated mutations after adjusting for subtype, previous ART exposure, CD4, and HIV viral load [odds ratio (OR) 0.04, P < 0.001]. CD4 cell counts greater than 100 cells/ml remained independently protective of multiple NRTI mutations (100-199: OR 0.3, P ¼ 0.03; !200: OR 0.4, P ¼ 0.09). Age, baseline CD4 cell counts (cells/ml), adherence, and length of time on ART did not significantly improve the analysis and were not retained in the final model. Forty-one percentage utilized the TAM 2 pathway and 32% utilized the TAM 1 pathway. Average HIV viral loads were lower for TAM 2 as compared to TAM 1 (4.5 vs. 4.9 log 10 copies/ml; P ¼ 0.02). Those who developed TAMs were more likely to be negative for the K65R mutation (70 vs. 12%; P < 0.001). D67N and K219E were the TAMs seen with K65R in the three patients who had both. Patients with TAMs had a longer median time on ART (32 vs. 23 months; P ¼ 0.06).
Non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance Among all patients genotyped, 97% patients had at least one NNRTI mutation and 47% had two or more etravirine-associated mutations. The most frequent NNRTI mutations were Y181C/V (43%) and K103N (37%). The L100I (36%), K103N (79%), and P225H (21%) mutations were more common in EFV-based regimens as compared to NVP-based regimens (Table 3) .
Three patients had selected IAS protease inhibitor major mutations (I50V, N83D, I84V, and L90M). Secondary mutations related to polymorphisms [I13V (95%), M36I (83%), H69K (82%), V82I (43%), and L63P (28%)] also occurred among those genotyped.
Effect of mutation patterns on second-line regimen options Overall, 41% of patients genotyped did not have an active NRTI option for a second-line regimen. However, the sensitivity for second-line NRTI options varied depending upon the first-line regimen (Fig. 1) .
Using the WHO 2010 guidelines, TDF was fully active for 52-58% of patients who received ZDV or d4T; and 39% who received more than one NRTI. The sensitivity did not differ if the multiple first-line regimens included ZDV and d4T (38%) or the regimens included ZDV or d4T before TDF (39%). However, patients who had TDF as a first-line regimen were 100% sensitive to ZDVand 70% sensitive to d4T. Furthermore, 70% of patients on TDF-based regimens had at least two options of NRTIs to include in a second-line regimen compared with 40% on ZDV-based regimens (OR ¼ 3.4, P ¼ 0.04). Overall, 85% of patients genotyped had intermediate to high-level resistance to the second-line option, etravirine (Table 3) . For protease inhibitors, there was predicted phenotypic resistance to nelfinavir and decreased virological response to tipranavir/ritonavir in one patient, as well as predicted intermediate resistance to lopinavir, atazanavir, or saquinavir with ritonavir in two patients, and to darunavir/ritonavir in one patient. There was no documented exposure to protease inhibitors in these patients.
Discussion
Tenofovir-based first-line regimens resulted in significantly fewer NRTI mutations and more fully active NRTI drugs to include in a second-line regimen for this small study of patients at high risk of virologic failure. TDF-based first-line regimen retained sensitivity to ZDV and a high proportion retained sensitivity to d4T. In comparison, only about half of the patients on ZDV or d4T retained full sensitivity to their recommended second-line NRTI, TDF, because of widespread accumulation of TAMs, known to mediate cross-resistance to all NRTIs [27] .
We report 57% of patients (13/23) on TDF-based regimens had K65R, a relatively uncommon mutation (1.7-4%) in viruses of subtype B [28] . K65R is selected by TDF, didanosine, stavudine, and abacavir [29] , but it may be emerging at higher frequencies among non-B subtypes exposed to TDF. Similar prevalences of K65R in TDF-based regimens were reported by other studies of non-B subtypes [30, 31] . In-vitro studies suggest that K65R develops more readily in subtype C because of a No. (%) of NRTI regimen Multiple first-line regimens: ZDV/d4T refers to switching from ZDV to d4T or d4T to ZDV; ZDV/d4T TDF, refers to switching from ZDV or d4T to TDF. One participant switched from TDF to ZDV and was not included as a third category for multiple first-line regimens because of the small sample size (n ¼ 1). (25) 38 (29) 1 (7) 4 (14) 2 62 (47) 6 (43) 10 (34) 3þ 27 (21) 7 (50) 13 ( (20) 27 (21) 2 (14) 6 (21) 0.6 1 56 (32) 46 (35) 6 (43) 3 (10) 2 55 (31) 42 (32) 3 (21) 10 (34) 3þ 29 (17) 16 (12) 3 (21) 10 ( site-specific pause on the viral template during transcription [32] , and this same mechanism may occur for subtypes found in Nigeria. ZDV and stavudine remain fully active with K65R, but abacavir and didanosine have reduced activity [33, 34] . TDF is partially active and it is enhanced when K65R co-occurs with M184V [35, 36] . M184V was the most frequent mutation among TDFbased regimens and the only one associated with a lower mean HIV-1 RNA viral load. Viruses with M184V have a decreased replicative capacity and its presence may suggest adherence [37, 38] . M184I (7/23) and Y115F (3/23) are relatively uncommon mutations, but occurred more often for those on TDF. The M184I may eventually switch to M184V and Y115F may be increasing for those on TDF, but the small numbers limit our inferences [39, 40] . Further studies are needed to evaluate the potential impact of different mutation patterns that are arising in non-B subtypes experiencing selective pressure from TDF.
Only 12% of patients with the K65R mutation developed TAMs compared with 70% of those without the K65R mutation. Other studies have shown there is an antagonistic relationship between TAMs and K65R [41, 42] . For those with frequent numbers of TAMs, slightly more study patients used the TAM 2 pathway and they had lower average HIV-1 RNA viral loads. Prior studies have shown that the TAM 2 pathway has lower levels of TDF resistance [43] , increased sensitivity to ZDV with M184V [44] , and slower rates of TAM acquisition [45] . Although this augurs well for second-line options, further studies are needed to confirm use of the TAM 2 pathway among non-B subtypes.
High levels of drug resistance in this study mirror findings in populations who have defined virologic failure with clinical and immunologic parameters rather than viral load testing [45] [46] [47] . Relying on such measures to define virologic failure increases the number of patients on suboptimal second-line regimens ultimately leading to poorer treatment outcomes [48] [49] [50] . It is imperative that viral load testing is conducted in order to maintain effective second-line options in low-resource settings.
Limitations of this study include its retrospective nature and its small numbers of patients receiving TDF or ZDV. Larger prospective studies are needed to estimate rates of drug resistance in these first-line regimens. At the time, d4Twas a recommended first-line regimen, but PEPFAR and national guidelines promoted substituting TDF because of d4T's associated toxicity issues [17, [51] [52] [53] . This study provided a unique opportunity to evaluate TDF as a first-line regimen. Another limitation was relying on predicted resistance patterns from algorithms without confirmation from phenotypic assays [54] . These assays require great resources and may not always be an option in low-resource settings. In addition, there were limited data on baseline mutation patterns, prior ART regimens, adherence, and archived and minority species, all of which could have better described the risk status of this population and whether it biased the mutation patterns observed for TDF and the other first-line regimens.
Our data suggest that TDF may be an optimal first-line regimen because it maintains susceptibility to thymidine analog drugs in second-line regimens. TDF has an increased tolerability which may foster adherence, limit multidrug resistance patterns, and promote longterm success for HIV/AIDS treatment programs. However, TDF is also associated with an increased frequency of the mutation K65R. The long-term effects of this mutation are unclear and ongoing monitoring of virologic failure is critical in guiding selection of NRTIs in resource-limited settings.
Sequence data
Sequences have been deposited in the GenBank Sequence Database under the following accession numbers: HQ843507-HQ843681.
